| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Service of Bone Diseases [World Health Organization Collaborating Center for Osteoporosis Prevention], Department of Rehabilitation and Geriatrics, Geneva University Hospital, Geneva 1211, Switzerland
Address all correspondence and requests for reprints to: Serge Ferrari, Service of Bone Diseases, Geneva University Hospital, 24 rue Micheli-du-Crest, Geneva 1211, Switzerland. E-mail: serge.ferrari{at}medecine.unige.ch.
The renal handling of inorganic phosphate (Pi) is controlled not only by PTH, but also by hitherto undetermined mechanisms dependent on phosphate intake. Recently, fibroblast growth factor (FGF)-23 was identified as a novel phosphaturic factor in tumor-induced osteomalacia and autosomal-dominant hypophosphatemic rickets. We hypothesized that phosphate intake could influence FGF-23 concomitantly to the changes in renal Pi handling. Twenty-nine healthy males were subjected to a 5-d low-phosphate diet and a phosphate binder, followed by a high-phosphate diet including supplements. Concomitant modifications in calcium intake allowed minimizing PTH changes in response to dietary phosphate. Serum FGF-23 levels significantly decreased on the low-phosphate diet, then increased with the oral phosphate load. Changes in FGF-23 were positively correlated with changes in 24-h urinary Pi excretion and negatively correlated with changes in the maximal tubular reabsorption of Pi and 1,25(OH)2D3 (calcitriol), whereas PTH was not. In multivariate analysis, changes in FGF-23 remained the most significantly correlated to changes in 1,25(OH)2D3 and maximal tubular reabsorption of Pi. Moreover, FGF-23 was positively correlated to serum osteocalcin, a marker of osteoblastic activity.
In summary, FGF-23 was inversely related to renal Pi transport and serum calcitriol levels in healthy young men. These data suggest that FGF-23 may be implicated in the physiological regulation of Pi homeostasis in response to dietary phosphate changes, independent of PTH.
This article has been cited by other articles:
![]() |
S. Goto, H. Komaba, and M. Fukagawa Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention NDT Plus, August 1, 2008; 1(suppl_3): iii2 - iii8. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Danziger The bone-renal axis in early chronic kidney disease: an emerging paradigm Nephrol. Dial. Transplant., May 9, 2008; (2008) gfn260v1. [Full Text] [PDF] |
||||
![]() |
G. van Boekel, J. Ruinemans-Koerts, F. Joosten, P. Dijkhuizen, A. van Sorge, and H. de Boer Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling Eur. J. Endocrinol., March 1, 2008; 158(3): 431 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Isakova, O. Gutierrez, A. Shah, L. Castaldo, J. Holmes, H. Lee, and M. Wolf Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKD J. Am. Soc. Nephrol., March 1, 2008; 19(3): 615 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Kunzendorf, B. K. Kramer, W. Arns, J. Braun, J. Grossmann, F. Pietruck, H. Schmidt-Gayk, A. Schwarz, E. Ziegler, H. Sperschneider, et al. Bone disease after renal transplantation Nephrol. Dial. Transplant., February 1, 2008; 23(2): 450 - 458. [Full Text] [PDF] |
||||
![]() |
L. Thomas and R. Kumar Control of Renal Solute Excretion by Enteric Signals and Mediators J. Am. Soc. Nephrol., February 1, 2008; 19(2): 207 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-A. Westerberg, T. Linde, B. Wikstrom, O. Ljunggren, M. Stridsberg, and T. E. Larsson Regulation of fibroblast growth factor-23 in chronic kidney disease Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3202 - 3207. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. SITARA Correlation among Hyperphosphatemia, Type II Sodium Phosphate Transporter Activity, and Vitamin D Metabolism in Fgf-23 Null Mice Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 485 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kawata, Y. Imanishi, K. Kobayashi, T. Miki, A. Arnold, M. Inaba, and Y. Nishizawa Parathyroid Hormone Regulates Fibroblast Growth Factor-23 in a Mouse Model of Primary Hyperparathyroidism J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2683 - 2688. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fliser, B. Kollerits, U. Neyer, D. P. Ankerst, K. Lhotta, A. Lingenhel, E. Ritz, F. Kronenberg, and for the MMKD Study Group Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2600 - 2608. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Canadillas, A. Rodriguez-Benot, and M. Rodriguez More on the bone-kidney axis--lessons from hypophosphataemia Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1521 - 1523. [Full Text] [PDF] |
||||
![]() |
S. Ferrari Single Gene Mutations and Variations Affecting Bone Turnover and Strength: a Selective 2006 Update IBMS BoneKEy, December 1, 2006; 3(12): 11 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Antoniucci, T. Yamashita, and A. A. Portale Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3144 - 3149. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, W. Tang, J. Zhou, J. R. Stubbs, Q. Luo, M. Pi, and L. D. Quarles Fibroblast Growth Factor 23 Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1305 - 1315. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rendina, G. Mossetti, G. De Filippo, M. Cioffi, and P. Strazzullo Fibroblast Growth Factor 23 Is Increased in Calcium Nephrolithiasis with Hypophosphatemia and Renal Phosphate Leak J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 959 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Schipani, A. Zallone, G. J. Strewler, J. W. Pike, S. Ferrari, Y. Jiang, and E. Seeman Meeting Report from the 27th Annual Meeting of the American Society for Bone and Mineral Research: September 23-27, 2005 in Nashville, Tennessee, USA IBMS BoneKEy, January 1, 2006; 3(1): 29 - 62. [Full Text] [PDF] |
||||
![]() |
X. Yu, O. A. Ibrahimi, R. Goetz, F. Zhang, S. I. Davis, H. J. Garringer, R. J. Linhardt, D. M. Ornitz, M. Mohammadi, and K. E. White Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23 Endocrinology, November 1, 2005; 146(11): 4647 - 4656. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Larsson, S. I. Davis, H. J. Garringer, S. D. Mooney, M. S. Draman, M. J. Cullen, and K. E. White Fibroblast Growth Factor-23 Mutants Causing Familial Tumoral Calcinosis Are Differentially Processed Endocrinology, September 1, 2005; 146(9): 3883 - 3891. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fukagawa and J. J. Kazama With or without the kidney: the role of FGF23 in CKD Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1295 - 1298. [Full Text] [PDF] |
||||
![]() |
T. Berndt and R. Kumar The Phosphatonins and the Regulation of Phosphorus Homeostasis IBMS BoneKEy, June 1, 2005; 2(6): 5 - 16. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |